← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #955 OF 1,000 MOST-CITED

Failure to comply with REMS Implementation System

FDA cited this observation 14 times across 13 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs14
BY FISCAL YEAR
FY20256
FY20242
FY20231
FY20221
FY20212
FY20191
FY20181

How FDA worded it — real examples

An application holder did not comply with the audit plan and schedule described in the REMS, as required by your approved REMS Implementation System.

Avadel CNS Pharmaceuticals LLC · Chesterfield, Missouri · Drugs · 2025-09-12

An application holder did not maintain the drug distribution and dispensing records to ensure restricted distribution, as required by your approved REMS Implementation System.

Daiichi Sankyo, Inc. · Basking Ridge, New Jersey · Drugs · 2025-08-01

An application holder did not comply with the audit plan and schedule described in the REMS and maintain the drug distribution and dispensing records to ensure restricted distribution, as required by your approved REMS Implementation System.

Alexion Pharmaceuticals, Inc. · Boston, Massachusetts · Drugs · 2025-03-07

An application holder did not comply with the audit plan and schedule described in the REMS, as required by your approved REMS Implementation System.

Celgene Corporation · Summit, New Jersey · Drugs · 2024-12-06

An application holder did not maintain the drug distribution and dispensing records to ensure restricted distribution, as required by your approved REMS Implementation System.

Bausch Health US., LLC. · Bridgewater, New Jersey · Drugs · 2024-11-07

An application holder did not comply with the audit plan and schedule described in the REMS and maintain the drug distribution and dispensing records to ensure restricted distribution, as required by your approved REMS Implementation System.

Actelion Pharmaceuticals US Inc. · Titusville, New Jersey · Drugs · 2024-10-28

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Quality risk managementPharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →